A Look At Vericel (VCEL) Valuation After Strong Preliminary Growth And Profitability Guidance

Simply Wall St.

01/16

AdvertisementWhy Vericel’s latest guidance is drawing fresh attention Vericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603930894"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603930894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603930894?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-16 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603930894","market":"sg","top_or_hot":-1,"title":"A Look At Vericel (VCEL) Valuation After Strong Preliminary Growth And Profitability Guidance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Vericel’s latest guidance is drawing fresh attention Vericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/a-look-at-vericel-vcel-valuation-after-strong-preliminary-gr\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Vericel (VCEL) Valuation After Strong Preliminary Growth And Profitability Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Vericel (VCEL) Valuation After Strong Preliminary Growth And Profitability Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 04:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/a-look-at-vericel-vcel-valuation-after-strong-preliminary-gr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Vericel’s latest guidance is drawing fresh attention Vericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/a-look-at-vericel-vcel-valuation-after-strong-preliminary-gr\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCEL","symbol_name":"Vericel Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/a-look-at-vericel-vcel-valuation-after-strong-preliminary-gr","article_id":"2603930894","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/a-look-at-vericel-vcel-valuation-after-strong-preliminary-gr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603930894","pubTimestamp":1768508869,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Vericel’s latest guidance is drawing fresh attention\nVericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 million in 2025 net revenue, and GAAP profitability for a second straight year.\nSee our latest analysis for Vericel.\nVericel’s latest guidance lands after a mixed share price performance, with a 7 day share price return of a 7.48% decline, a 90 day share price return of 7.42%, and a 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCEL":"Vericel Corporation","BK4139":"生物科技"},"translate_title":"在强劲的初步增长和盈利指引后审视Vericel(VCEL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCEL":1.5},"content_text":"AdvertisementWhy Vericel’s latest guidance is drawing fresh attention Vericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 million in 2025 net revenue, and GAAP profitability for a second straight year. See our latest analysis for Vericel. Vericel’s latest guidance lands after a mixed share price performance, with a 7 day share price return of a 7.48% decline, a 90 day share price return of 7.42%, and a 1 year total shareholder return of a 35.13% decline. This suggests recent enthusiasm is still working against a weaker longer term record as investors reassess growth potential and risk around its burn and sports medicine franchises. If Vericel’s update has you thinking about where else growth stories might emerge in healthcare, it could be a good moment to scan healthcare stocks as a source of fresh ideas. With Vericel projecting US$276 million in 2025 revenue, remaining profitable on GAAP terms, and the share price still 35% below its 1-year level, is this a reset entry point, or has the market already accounted for future growth? Most Popular Narrative: 30.7% Undervalued Against Vericel’s last close of US$37.33, the most followed narrative points to a higher fair value, built on detailed growth and margin assumptions.  In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 45.8x on those 2028 earnings, down from 231.0x today. This future PE is greater than the current PE for the US Biotechs industry at 15.3x.  Read the complete narrative. Analysts are outlining a step change in profitability, supported by faster revenue growth and a sharply different earnings multiple. Curious how those pieces fit together into that higher fair value? Result: Fair Value of $53.88 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on a narrow product lineup and higher operating costs, so slower procedure uptake or reimbursement pushback could quickly challenge that underpriced growth story. Find out about the key risks to this Vericel narrative. Another angle on valuation The popular narrative calls Vericel 30.7% undervalued, but its current P/E of 144.3x tells a very different story. That is far above both the US Biotechs average of 20.2x and the 52.1x peer average. It also sits well above the 24.3x fair ratio our models suggest the market could move toward over time. If earnings or sentiment slip, that kind of gap can matter, because even a partial reset toward the fair ratio would mean a very different outcome compared with the optimistic narrative. So is this a case of the market getting ahead of itself, or are you comfortable paying up for the growth profile? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:VCEL P/E Ratio as at Jan 2026 Build Your Own Vericel Narrative If you are not fully aligned with this view, or simply like to run your own numbers, you can build a complete narrative in just a few minutes. Start with Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Vericel. Looking for more investment ideas? If Vericel has sharpened your thinking, do not stop here. Casting a wider net across different themes can help you spot opportunities you might otherwise miss.  Target higher income potential by scanning these 12 dividend stocks with yields > 3% that may suit an income focused watchlist. Spot early tech shifts by checking out these 24 AI penny stocks that tie artificial intelligence to real business models. Hunt for value by reviewing these 875 undervalued stocks based on cash flows that currently screen as mispriced based on cash flows.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}